Case Study

Ipsen: Accelerating profitable growth in pharma

27 pages
February 2024
Reference: IMD-7-2510

Part One: Ipsen, a global pharmaceutical firm headquartered in France, was facing significant challenges, including regulatory setbacks and fierce competition, when David Loew assumed the role of CEO in 2020. The loss of exclusivity for Somatuline, Ipsen’s flagship cancer drug, added to the complexities. Tasked by the board, Loew aimed to lead Ipsen into a new era of profitable growth amid escalating competition. After thorough review during the Covid-19 pandemic, Loew and the executive team recognized the critical importance of the upcoming strategy. Ipsen Investors’ Day became the platform to unveil “Focus. Together. For Patients and Society,” the strategy shaping Ipsen’s trajectory toward ambitious 2025 targets. Despite pandemic disruptions, Loew was confident that Ipsen possessed the essential elements to embark on a new path of profitable growth. Part Two: Three years after launching the new strategy, David Loew concluded a meeting with the head of legal affairs, reflecting on the strategy’s journey. Structured around four pillars, the strategy prioritized patient-centricity, a sustainable pipeline, improved efficiency and operational excellence through collaboration and a diverse workforce. Ipsen’s ambition was to be an adaptable force, creating lasting value. While Ipsen made significant strides in executing the strategy, recognizing market acknowledgment, critical questions persisted. These revolved around geographic footprint, digital integration, ongoing cultural transformation and the accelerated development of key products alongside acquisitions to fortify the pipeline. Loew prepared for a two-day session with the executive team to capitalize on successes and chart the way forward to future-proof the company.

Learning Objective
  • Understand Ipsen’s strategic transformation: Gain insights into its transformation journey, from its historical roots to its current strategic direction under David Loew’s leadership.
  • Understand Ipsen’s competitive environment and the macro factors that have shaped the pharma industry and will influence its future evolution.
  • Explore the need for a mid-sized global pharma to design a new strategy in view of likely future disruptions to the sector.
  • Explore strategy design in a highly competitive industry.
  • Think holistically about how to approach the design of a multi-year corporate strategy.
Growth, Customer Centricity, Research and Development, Efficiency, Acquisition, Good Health, Well-being
Ipsen, Healthcare, Biopharmaceuticals, Pharmaceuticals
Field Research
© 2024
Available Languages
Related material
Teaching note
Case clearing houses
IMD case studies are distributed through case clearing houses. In order to browse the collection and purchase copies please visit the links below.

The Case Centre

Cranfield University

Wharley End Beds MK43 0JR, UK
Tel +44 (0)1234 750903
Email [email protected]

Harvard Business School Publishing

60 Harvard Way, Boston MA 02163, USA
Tel (800) 545-7685 Tel (617)-783-7600
Fax (617) 783-7666
Email [email protected]

Asia Pacific Case Center

NUCB Business School

1-3-1 Nishiki Naka
Nagoya Aichi, Japan 460-0003
Tel +81 52 20 38 111
Email [email protected]


Research Information & Knowledge Hub for additional information on IMD publications

Discover our latest research
IMD's faculty and research teams publish articles, case studies, books and reports on a wide range of topics